ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Bolsters Rare Disease Pipeline With FDA Nod for Wayrilz in Chronic ITP
Sanofi announced that the US FDA has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who had an insufficient response to previous treatments, based on positive outcomes from the pivotal LUNA 3 phase 3 study.
This approval not only introduces a novel Bruton’s tyrosine kinase inhibitor for ITP but also leverages Fast Track and Orphan Drug Designations for broader rare disease market potential.
Now, we’ll explore how the FDA approval of...